We identified branded antidepressant and antipsychotic launches between 2003 and 2010. Market authorisation dates and P&R dates were sourced from national databases and launch dates were determined using IMS MIDAS data. The average time between market authorisation, P&R and launch was then calculated for fifteen European countries. RESULTS: In most countries the identified products were not launched until P&R was secured, making it a significant barrier to patient access. The average time taken to achieve P&R was approximately 310 days, with significant variation between countries. This delay was frequently longer than the average P&R delay seen across all therapy areas. On average only the UK, Germany and Denmark achieved P&R within Transparency Directive guidelines. Significant delays were seen in Portugal and France, taking on average 550 and 610 days respectively to gain P&R. CONCLUSIONS: In addition to known development challenges for CNS products, manufacturers experience greater delays in securing P&R in Europe, denying patients timely access to these drugs. Few countries comply with the current Transparency Directive [2], and if proposed changes are implemented to reduce the delay to 120 days, even fewer will be compliant. P&R is an additional hurdle to access that particularly impacts CNS drugs, and stronger efforts to reduce these delays are needed. 
OBJECTIVES: A reimbursement prediction model was previously developed based on a dataset of submissions to the Scottish Medicines Consortium (SMC) between 2008 and 2010. The aim was to update and re-analyze the dataset, and to test internal and external validity of the prediction model on submissions from 2011 and 2012. METHODS: A database of submissions between January 2005 and March 2012 was created. Data of 405 applications were collected, including information on the reimbursement decision (yes/no), clinical data and indicators of the health economic model quality supporting the submission. The impact of these variables was estimated with univariate and multivariate logistic regression models. The multivariate model was identified by a backward selection procedure. Internal validity was assessed by the area under the receiver operating characteristic (ROC) curve. External validity was conducted and judged by a classification test to predict the SMC decision based on 2011-2012 data. RESULTS: Out of 405 applications 226 received positive recommendation (56%) and 131 (58%) of them were reimbursed with restriction, e.g. limited patient population or restricted time period. Based on univariate analyses, three factors had the largest significant effect on the reimbursement: poor pharmacoeconomic analysis design (ORϭ0.03), high ICER (ORϭ0.16) and unclear/ inferior efficacy outcomes (ORϭ0.25). The final multivariate model included the following further factors: antineoplastic-immunomodulating agent (ORϭ0.47), combination therapy (ORϭ2.00), biological drug (ORϭ0.16), placebo-uncontrolled trial (ORϭ0.50), extended indication (ORϭ4.24), innovative drug (ORϭ2.07). The area under the ROC curve was high; 87.7%. Based on the external validation, using a model estimated on data until December 2010 and a cut-off point of 50%, 79.8% of the predicted reimbursement decisions in 2011-2012 were correctly classified. CONCLUSIONS: The new prediction model demonstrates internal and external validity for [2011] [2012] . Therefore, the model could be used as input when further optimizing the market access strategy for products in clinical development. 
RE2 A DETAILED COMPARISON OF DUTCH AND SWEDISH DRUG REIMBURSEMENT DECISIONS: WHAT EVIDENCE IS AVAILABLE, WHICH CRITERIA ARE USED, AND IS THE DECISION-MAKING PROCESS TRANSPARENT?

OBJECTIVES:
To compare Dutch and Swedish drug reimbursement decisions and to investigate the available evidence, used criteria, outcomes and transparency of the decision-making process. METHODS: We investigated Dutch and Swedish publicly available drug reimbursement dossiers from 2005 until July 2011. Applications and outcomes were compared and classified into different categories. For dossiers that included a full pharmacoeconomic evaluation (i.e. cost-effectiveness and/ or cost-utility analysis) in both countries, we compared in detail how the available evidence was assessed to appraise societal value. RESULTS: Pharmacoeconomic evaluations were more often available in Swedish dossiers due to many exemptions in The Netherlands (mainly orphan and HIV drugs). Reimbursement dossiers only provided a full economic evaluation in both countries for eleven drugs. The reimbursement decision differed for four drugs, in which relatively more restrictions were observed. Although Dutch dossiers provided more details, all dossiers included information of underlying clinical and economic studies. Comparators were always reported. Using a similar comparator (8x) resulted in a similar (5x) and a different (3x) therapeutic value judgement, while a different comparator (3x) resulted twice in a similar judgement. Swedish 'yes' decisions (10x) were judged cost-effective; 'no' decisions (two for one drug) were judged cost-ineffective. Dutch 'yes' decisions (9x, including two second decisions) were evaluated sufficiently (3x), reasonably (1x), moderately (2x), and insufficiently (3x) founded pharmacoeconomic evidence; all 'no' decisions (4x) were insufficiently founded. Appraisal elements were descriptively reported. The (high) severity of the disease was explicitly mentioned in three overlapping cases. However, the actual influence of disease severity on the final 'yes' decision remained unclear. CONCLUSIONS: Both countries make their reimbursement reports publicly available. Although the assessment is reasonable transparent, both countries could improve transparency of the appraisal process by more explicitly showing the actual role of each different (societal) criterion in drug reimbursement decision making.
RE3 HOW WILL THE NEW NHS CHANGES IN ENGLAND IMPACT THE IMPLEMENTATION OF RISK-SHARING SCHEMES FOR ONCOLOGY TREATMENTS?
Jeffery M, Assimakopoulos M, White R Access Partnership, London, UK OBJECTIVES: With the current English NHS reforms will the new Clinical Commissioning Groups (CCGs) follow an Italian type regional approach to enable patient access to innovative and premium priced medicines when implementing patient access schemes. METHODS: We reviewed the current structures of the first wave CCGs and their association with the local oncology networks, new commissioning support bodies and oncology centres to assess the practicality of implementing current patient access schemes. We also reviewed new schemes approved by the Italian medicines agency, AIFA, to accelerate reimbursement for new drugs especially when there is limited availability at launch. RESULTS: It is clear that the suggested circa 200 proposed CCGs will have limited resources to fund suitable management structures to run risk share/patient access scheme effectively. Spend on pharmaceuticals, especially with public and physician demand, for innovative premium cost cancer treatments, will now be led and influenced by General Practitioners (GPs). The critical question facing family GPs will be how can they address the funding of these high cost treatments yet still satisfy patient demand. One approach that could be adopted to a new type of patient access scheme is now being lead by AIFA who have developed an approach to enhance the reimbursement potential of innovative anti-cancer medicines. CONCLUSIONS: The new commissioning support bodies recently appointed by the English Department of Health's, National Commissioning Board, could easily follow the Italian suggested approach; to help provide decision-making GPs with a framework to assess new premium prices medicines, outside of the current support provided by NICE and the Patient Access Scheme Liaison Unit. 
RE4 BEYOND THE EVIDENCE -THE INFLUENCE OF DECISION PROCESSES ON OUTCOMES IN COVERAGE DETERMINATION OF HEALTH TECHNOLOGIES
OBJECTIVES:
Coverage decision processes determine the accessibility of health technologies. Cost-effectiveness considerations have been identified to explain decision outcomes. Beyond the evidence, outcomes may be influenced by the process configurations used by decison makers. The aim of this exploratory study was to analyse the influences of transparency, stakeholder participation, scientific rigour of assessment and evidence judgments on decision outcomes in coverage decision-making. METHODS: Using survey data of 77 decisions from 13 countries, we examined whether outcomes differ by 14 variables that describe components of coverage decision-making and the technology considered for coverage. Neglecting the level of reimbursement, we analysed the likelihood of committees to cover a technology, i.e. positive (including partial coverage) vs. negative coverage decisions. We performed non-parametric univariate statistical tests and binomial logistic regression. To identify influences on decision outcomes, we applied a stepwise variable selection procedure. RESULTS: We identified associations between the decision outcome and the following variables: the technology is a prescribed medicine (pϭ0.0097); the health condition is an endocrine, nutritional or metabolic disease (pϭ0.0311) and the judgment of the evidence after assessment (pϽ0.0001). The first estimation of the logistic regression model suggested a quasi-complete separation for those decisions where effectiveness and costs/cost-effectiveness A287 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
